A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

ConditionsHER2-positive Advanced Gastric Cancer HER2-positive Gastroesophageal Junction Adenocarcinoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

About this trial

Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

This study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.

Eligibility criteria

Qualifiers

Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GEJ adenocarcinoma who have received a prior trastuzumab based regimen

Histological or cytological confirmed diagnosis of advanced HER2 positive gastric cancer or GEJ

Documented HER2 + status (archival sample or recent sample prior 2L therapy)

Decision to newly initiate monotherapy T-DXd or conventional therapies per SMPC according to the physician's choice

Disqualifiers

Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded

Pregnancy or breastfeeding

Trial design

Treatments tested in this trial

Trastuzumab deruxtecan

Treatment groups

257 Participants

are divided into 1 treatment group

Locations76

Select a site below to view it on the map.

Austria

Belgium

Germany

Italy

Portugal

Sponsors and collaborators

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Lead sponsor

Source ClinicalTrials.gov